Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: May 31, 2022
Understanding
and
measuring
the
individual
level
of
immune
protection
its
persistence
at
both
humoral
cellular
levels
after
SARS-CoV-2
vaccination
is
mandatory
for
management
booster
campaign.
Our
prospective
study
was
designed
to
assess
immunogenicity
BNT162b2
mRNA
vaccine
in
triggering
response
healthcare
workers
up
12
months
initial
vaccination,
with
one
additional
boosting
dose
between
6
months.
Immunological Reviews,
Journal Year:
2022,
Volume and Issue:
310(1), P. 27 - 46
Published: June 22, 2022
Immunological
memory
is
the
basis
of
protective
immunity
provided
by
vaccines
and
previous
infections.
can
develop
from
multiple
branches
adaptive
immune
system,
including
CD4
T
cells,
CD8
B
long-lasting
antibody
responses.
Extraordinary
progress
has
been
made
in
understanding
to
SARS-CoV-2
infection
COVID-19
vaccines,
addressing
development;
quantitative
qualitative
features
different
cellular
anatomical
compartments;
durability
each
component
antibodies.
Given
sophistication
measurements;
size
human
studies;
use
longitudinal
samples
cross-sectional
head-to-head
comparisons
between
or
for
1
year
already
supersedes
that
any
other
acute
infectious
disease.
This
knowledge
may
help
inform
public
policies
regarding
as
well
scientific
development
future
against
diseases.
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: Feb. 16, 2022
Population
antibody
surveillance
helps
track
immune
responses
to
COVID-19
vaccinations
at
scale,
and
identify
host
factors
that
may
affect
production.
We
analyse
data
from
212,102
vaccinated
individuals
within
the
REACT-2
programme
in
England,
which
uses
self-administered
lateral
flow
tests
sequential
cross-sectional
community
samples;
71,923
(33.9%)
received
least
one
dose
of
BNT162b2
vaccine
139,067
(65.6%)
ChAdOx1.
For
both
vaccines,
positivity
peaks
4-5
weeks
after
first
then
declines.
At
21
days
second
BNT162b2,
close
100%
respondents
test
positive,
while
for
ChAdOx1,
this
is
significantly
reduced,
particularly
oldest
age
groups
(72.7%
[70.9-74.4]
ages
75
years
above).
decreases
with
age,
higher
females
those
previous
infection.
Antibody
lower
transplant
recipients,
obese
individuals,
smokers
specific
comorbidities.
These
will
benefit
additional
doses.
Cell,
Journal Year:
2023,
Volume and Issue:
186(11), P. 2392 - 2409.e21
Published: April 13, 2023
T
cell
responses
play
an
important
role
in
protection
against
beta-coronavirus
infections,
including
SARS-CoV-2,
where
they
associate
with
decreased
COVID-19
disease
severity
and
duration.
To
enhance
immunity
across
epitopes
infrequently
altered
SARS-CoV-2
variants,
we
designed
BNT162b4,
mRNA
vaccine
component
that
is
intended
to
be
combined
BNT162b2,
the
spike-protein-encoding
vaccine.
BNT162b4
encodes
variant-conserved,
immunogenic
segments
of
nucleocapsid,
membrane,
ORF1ab
proteins,
targeting
diverse
HLA
alleles.
elicits
polyfunctional
CD4+
CD8+
animal
models,
alone
or
when
co-administered
BNT162b2
while
preserving
spike-specific
immunity.
Importantly,
demonstrate
protects
hamsters
from
severe
reduces
viral
titers
following
challenge
variants.
These
data
suggest
a
combination
could
reduce
duration
caused
by
circulating
future
currently
being
clinically
evaluated
BA.4/BA.5
Omicron-updated
bivalent
(NCT05541861).
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(6), P. 5944 - 5944
Published: March 21, 2023
The
application
of
BNT162b2
and
mRNA-1273
vaccines
against
SARS-CoV-2
infection
has
constituted
a
determinant
resource
to
control
the
COVID-19
pandemic.
Since
beginning
2021,
millions
doses
have
been
administered
in
several
countries
North
South
America
Europe.
Many
studies
confirmed
efficacy
these
wide
range
ages
vulnerable
groups
people
COVID-19.
Nevertheless,
emergence
selection
new
variants
led
progressive
decay
vaccine
efficacy.
Pfizer-BioNTech
Moderna
developed
updated
bivalent
vaccines-Comirnaty
Spikevax-to
improve
responses
Omicron
variants.
Frequent
booster
with
monovalent
or
mRNA
vaccines,
some
rare
but
serious
adverse
events
activation
T-helper
17
suggest
need
for
improved
formulations
use
other
types
vaccines.
In
this
review,
we
discuss
advantages
limitations
targeting
focusing
on
most
recent,
related
publications.
Nature Aging,
Journal Year:
2023,
Volume and Issue:
3(1), P. 82 - 92
Published: Jan. 12, 2023
Abstract
Whether
age-associated
defects
in
T
cells
impact
the
immunogenicity
and
reactogenicity
of
mRNA
vaccines
remains
unclear.
Using
a
vaccinated
cohort
(
n
=
216),
we
demonstrated
that
older
adults
(aged
≥65
years)
had
fewer
vaccine-induced
spike-specific
CD4
+
including
CXCR3
circulating
follicular
helper
H
1
subset
after
first
dose,
which
correlated
with
their
lower
peak
IgG
levels
systemic
adverse
effects
second
compared
younger
adults.
Moreover,
expressed
higher
programmed
cell
death
protein
1,
negative
regulator
activation,
was
associated
low
CD8
responses.
Thus,
an
inefficient
response
dose
may
reduce
production
cytokines,
even
thereby
lowering
humoral
cellular
immunity
reducing
reactogenicity.
Therefore,
enhancing
following
is
key
to
improving
vaccine
efficacy
